title: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
abstract: In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).
authors.affiliation: University Hospital, Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Brigitte
authors.initials: B
authors.lastname: Pégourié
authors.forename: Lucie
authors.initials: L
authors.lastname: Planche
authors.forename: Cyrille
authors.initials: C
authors.lastname: Hulin
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Stoppa
authors.forename: Jean-Gabriel
authors.initials: JG
authors.lastname: Fuzibet
authors.forename: Bernard
authors.initials: B
authors.lastname: Grosbois
authors.forename: Chantal
authors.initials: C
authors.lastname: Doyen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Catherine
authors.initials: C
authors.lastname: Sebban
authors.forename: Brigitte
authors.initials: B
authors.lastname: Kolb
authors.forename: Carine
authors.initials: C
authors.lastname: Chaleteix
authors.forename: Mamoun
authors.initials: M
authors.lastname: Dib
authors.forename: Laurent
authors.initials: L
authors.lastname: Voillat
authors.forename: Jean
authors.initials: J
authors.lastname: Fontan
authors.forename: Laurent
authors.initials: L
authors.lastname: Garderet
authors.forename: Jérôme
authors.initials: J
authors.lastname: Jaubert
authors.forename: Claire
authors.initials: C
authors.lastname: Mathiot
authors.forename: Dixie
authors.initials: D
authors.lastname: Esseltine
authors.forename: Hervé
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000328:Adult; D018572:Disease-Free Survival; D006801:Humans; D057194:Intention to Treat Analysis; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome